Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin crossover study of the incretin effect in metformin-treated type 2 diabetes
2006-001219-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novartis. Primary endpoints: Effect of vildagliptin on incretin-mediated enhancement of insulin secretion assessed by C-peptide IAUC (0-4 hours) and Effect of vildagliptin on incretin-mediated enhancement of insulin secretion assessed by insulin secretion rate relative to glucose (0-2 hours). Started Aug 2006; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-001219-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001219-31.